Chromocell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Net Income	-7.38	-2.46	-0.6	-0.66
Share-Based Compensation	1.73	0.11	0	0
Other Operating Activities	4.67	0.78	-1	-2.97
Operating Cash Flow	-0.98	-1.57	-1.59	-3.63
Share Issuance / Repurchase	0.26	0	0	0
Debt Issued / Paid	0.77	1.2	1.1	0.24
Other Financing Activities	-	0.42	0.49	3.38
Financing Cash Flow	1.02	1.62	1.59	3.63
Net Cash Flow	0.04	0.06	0	0
Free Cash Flow	-0.98	-1.57	-1.59	-3.63
Free Cash Flow Margin	-	-	-	-1813.48%
Free Cash Flow Per Share	-0.77	-3.60	-1.43	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).